Halaven

Type: Product
Name: Halaven
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

HALAVEN® (ERIBULIN) NOW COMMERCIALLY AVAILABLE IN LEBANON FOR THE TREATMENT OF METASTATIC BREAST CANCER

Eisai partners with Abela Frères for the commercialisation of Halaven® (eribulin)Hatfield, UK, 07 April 2014 – Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania) today announces that Halaven® (eribulin) is now commercially available in Lebanon ... [Published PharmiWeb - Apr 08 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 4 reports

Eisai announces availability of Halaven in Lebanon for treatment of metastatic breast cancer

Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania) has announces that Halaven (eribulin) is now commercially available in Lebanon as a treatment for women with locally advanced or ... ... [Published Big News Network - Apr 07 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

CORCEPT THERAPEUTICS : US Oncology Research Joins Corcept Therapeutics' Phase I Breast Cancer Study

- Corcept Therapeutics Incorporated ( NASDAQ : CORT ), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, and US Oncology Research, ... [Published 4 Traders - Apr 02 2014]
First reported Feb 07 2014 - Updated Feb 07 2014 - 1 reports

Human medicines European public assessment report (EPAR): Halaven, eribulin, Revision: 6, Authorised

Entities: Halaven, Eribulin
First reported Feb 04 2014 - Updated Feb 04 2014 - 1 reports

Eisai's lenvatinib to follow in Nexavar's footsteps

| SCRIPLenvatinib, Eisai's next big oncology hope after breast cancer drug Halaven (eribulin), has met its primary endpoint in the Phase III SELECT trial in thyroid cancer patients. The company plans to submit marketing authorization applications for ... [Published BioPortfolio - Feb 04 2014]
First reported Jan 23 2014 - Updated Jan 23 2014 - 1 reports

The Pixie Awards Announces 2014 Competition Winners

5th Annual Competition Honors Outstanding Work in Motion Graphics, Visual Effects and Animation The Pixie Awards is proud to announce the winners of its 5th Annual Competition. The Pixie Awards honors outstanding work in Motion Graphics, Visual Effects ... [Published PRWeb - Jan 23 2014]
First reported Dec 16 2013 - Updated Dec 16 2013 - 1 reports

Halaven Plus Herceptin Winning Combo CMECE

SAN ANTONIO MedPage Today Treatment with the chemotherapy agent eribulin Halaven plus trastuzumab Herceptin extends progressionfree survival among women with metastatic breast cancer researchers said here. ... [Published BioPortfolio - Dec 16 2013]
First reported Dec 05 2013 - Updated Dec 05 2013 - 2 reports

Eisai Oncology to Present Data Analyses on Halaven eribulin at 36th Annual San Antonio Breast Cancer Symposium

Home » Syndicated Content » Eisai Oncology to Present Data Analyses on Halaven (eribulin) at 36th Annual San Antonio Breast Cancer SymposiumHATFIELD, England, December 5, 2013 /PRNewswire/ -- Eisai announced today that four abstracts highlighting new ... [Published BioPortfolio - Dec 05 2013]
First reported Nov 18 2013 - Updated Nov 18 2013 - 2 reports

Newbridge to market Eisai's breast cancer treatment Halaven across Middle East

Eisai has announced that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals.Eribulin ... [Published Pharmaceutical Business Review - Nov 18 2013]
First reported Nov 06 2013 - Updated Nov 06 2013 - 1 reports

Eisai To Use ThreeTiered Pricing In India For BreastCancer Drug

Home » Blogs » Eisai To Use Three-Tiered Pricing In India For Breast-Cancer DrugRelated Biotechnology, Pharmaceutical and Healthcare NewsEisai plans to extend its affordable-pricing system for certain drugs in India and other emerging markets to its third ... [Published BioPortfolio - Nov 06 2013]
Entities: Eisai Co Ltd, India, Drugs

Quotes

"We are committed to building a strong relationship with Eisai to ensure that Halaven reaches the people who need it in Lebanon,” said Antoine Fadel, Chief Executive Officer, Abela Frères. “Our extensive marketing and distribution experience in the region best positions us for this partnership.”"
Original Article: NEXT ARTICLE More From BioPortfolio on "Eisai announces availability of Halaven in Lebanon for treatment of metastatic breast cancer"
"We are committed to building a strong relationship with Eisai to ensure that Halaven reaches the people who need it in Lebanon"
...to benefit from its network of wide-ranging expertise in the field of oncology," said Joseph K Belanoff, M D , Corcept's Chief Executive Officer. "Their support and participation will allow patients to be enrolled rapidly as we move forward to complete our Phase I study."

More Content

All (21) | News (18) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
HALAVEN® (ERIBULIN) NOW COMMERCIALLY AVAILABLE ... [Published PharmiWeb - Apr 08 2014]
Eisai announces availability of Halaven in Leba... [Published Big News Network - Apr 07 2014]
Eisai announces availability of Halaven in Leba... [Published BioPortfolio - Apr 07 2014]
Eisai announces availability of Halaven in Leba... [Published PBR - News - Apr 07 2014]
Halaven® (Eribulin) Now Commercially Available ... [Published ADVFN UK - Apr 07 2014]
CORCEPT THERAPEUTICS : US Oncology Research Joi... [Published 4 Traders - Apr 02 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 07 2014]
Eisai's lenvatinib to follow in Nexavar's foots... [Published BioPortfolio - Feb 04 2014]
The Pixie Awards Announces 2014 Competition Win... [Published PRWeb - Jan 23 2014]
Halaven Plus Herceptin Winning Combo CMECE [Published BioPortfolio - Dec 16 2013]
Eisai Oncology to Present Data Analyses on Hala... [Published BioPortfolio - Dec 05 2013]
Eisai to Present New Research on Halaven Eribul... [Published BioPortfolio - Dec 05 2013]
Newbridge to market Eisai's breast cancer treat... [Published Pharmaceutical Business Review - Nov 18 2013]
Newbridge to market Eisai's breast cancer treat... [Published BioPortfolio - Nov 18 2013]
Eisai Announces Partnership With Newbridge to M... [Published Financial Services - Nov 18 2013]
Eisai To Use ThreeTiered Pricing In India For B... [Published BioPortfolio - Nov 06 2013]
Eisai Presents New Research on Halaven eribulin... [Published BioPortfolio - Sep 30 2013]
Eisai stellt neue Forschungsergebnisse zu Halav... [Published BioPortfolio - Sep 30 2013]
Eisai opens new office in Belgium [Published PharmaBiz - Sep 17 2013]
Eisai Launches Its First Drug In Russia A Breas... [Published BioPortfolio - Sep 13 2013]
Eisai Announces Availability of Halaven eribuli... [Published BioPortfolio - Jul 29 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Eisai announces availability of Halaven in Leba... [Published PBR - News - Apr 07 2014]
Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania) has announces that Halaven (eribulin) is now commercially available in Lebanon as a treatment for women with locally advanced or metastatic breast cancer who have previously received at least ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 07 2014]
1

Press Releases

sort by: Date | Relevance
Eisai Announces Partnership With Newbridge to M... [Published Financial Services - Nov 18 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.